LPCN Lipocine Inc.

3.40
+0.03  (0.89%)
Previous Close 3.37
Open 3.37
Price To book 2.20
Market Cap 62.08M
Shares 18,260,000
Volume 75,967
Short Ratio 9.97
Av. Daily Volume 170,971

SEC filingsSee all SEC filings

  1. SC 13G - Statement of acquisition of beneficial ownership by individuals 17522377
  2. 8-K - Current report 17515761
  3. 8-K - Current report 17509017
  4. 8-K - Current report 162032689
  5. S-8 - Securities to be offered to employees in employee benefit plans 161980014

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b top-line data released September 2016. Intends to meet FDA to discuss Phase 3 plans.
LPCN 1111
Oral testosterone product
CRL issued June 2016. Dosing flexibility trial to be initiated 1Q 2017 with data due in 2Q 2017.
LPCN 1021
Men with low testosterone (Low T)
Phase 3 protocol to be filed with FDA 1H 2017.
LPCN 1107
Prevention of preterm birth (“PTB”).

Latest News

  1. LIPOCINE INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  2. Lipocine Receives FDA Guidance on the Phase 3 Program for LPCN 1107, an Oral Alternative for the Prevention of Preterm Birth
  3. LPCN: Early Start to Tlando Validation Trial
  4. LIPOCINE INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  5. Lipocine Initiates a Dosing Flexibility Study for LPCN 1021, Its Oral Testosterone Replacement Product Candidate
  6. Lipocine, Inc. :LPCN-US: Earnings Analysis: Q3, 2016 By the Numbers : December 6, 2016
  7. LIPOCINE INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  8. Lipocine to Initiate Dosing Validation Study for LPCN 1021, Oral Testosterone Replacement Product Candidate
  9. LPCN Gets Lean Guiding Tlando Through Approval Process.
  10. LIPOCINE INC. Financials
  11. LIPOCINE INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Financial
  12. LIPOCINE INC. Files SEC form 10-Q, Quarterly Report
  13. Lipocine Announces Financial and Operational Results for the Third Quarter of 2016
  14. LIPOCINE INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  15. Lipocine Announces Issuance of US Patent 9,480,690
  16. LIPOCINE INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  17. Testosterone Ruling Gives Boost to Lipocine (LPCN)
  18. LIPOCINE INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  19. Here’s Why Lipocine Inc. (LPCN), Zillow Group Inc. (ZG) and Three Other Stocks Are Gaining Ground Today
  20. HC Wainwright's New Buy Rating On Lipocine Suggests 500% Upside

SEC Filings

  1. SC 13G - Statement of acquisition of beneficial ownership by individuals 17522377
  2. 8-K - Current report 17515761
  3. 8-K - Current report 17509017
  4. 8-K - Current report 162032689
  5. S-8 - Securities to be offered to employees in employee benefit plans 161980014
  6. 8-K - Current report 161980007
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 161980002
  8. 8-K - Current report 161976594
  9. 8-K - Current report 161938014
  10. 8-K - Current report 161928886